Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose subcutaneous flumazenil for benzodiazepine withdrawal
ACTRN12616001560482Phase 3Terminated
- Sponsor
- Go Medical Industries
- Start
- Aug 2017
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of flumazenil in benzodiazepine withdrawal syndrome (BWS) and benzodiazepine dependence (2 arms), sponsored by Go Medical Industries. Primary endpoint: Rate of symptom-triggered taper from benzodiazepines. Started Aug 2017; status: terminated.
02
Drugs
flumazenil
03
Conditions
benzodiazepine withdrawal syndrome (BWS)benzodiazepine dependence
Beyond the preview
Go deeper on ACTRN12616001560482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616001560482.